LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Home・Aktien・Avita Therapeutics Inc

Avita Therapeutics Inc

Geschlossen

4.28 0.47

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.1

Max

4.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.6M -12M
Verkäufe	554K 18M
EPS	-0.536
Gewinnspanne	-65.968
Angestellte	226
EBITDA	1.6M -9.7M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+8.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.9M 127M
Vorheriger Eröffnungskurs	3.81
Vorheriger Schlusskurs	4.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

8.83 / 9.77 Unterstützung & Widerstand

Avita Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Feb. 2026, 22:31 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. Feb. 2026, 22:18 UTC

Ergebnisse

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. Feb. 2026, 22:11 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. Feb. 2026, 21:52 UTC

Ergebnisse

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. Feb. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. Feb. 2026, 23:34 UTC

Market Talk

Ergebnisse

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. Feb. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. Feb. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. Feb. 2026, 22:45 UTC

Ergebnisse

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. Feb. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q EPS $1.18 >NTR.T

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q Sales $5.34B >NTR.T

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q EPS $1.07 >PAAS

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q Rev $1.18B >PAAS

18. Feb. 2026, 22:30 UTC

Ergebnisse

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. Feb. 2026, 22:29 UTC

Ergebnisse

Kinross Gold 4Q EPS 75c >K.T

18. Feb. 2026, 22:22 UTC

Ergebnisse

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. Feb. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. Feb. 2026, 22:16 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. Feb. 2026, 22:05 UTC

Ergebnisse

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. Feb. 2026, 22:03 UTC

Ergebnisse

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Sales $929M >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Adj EPS 67c >KGC

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Sales $2.02B >KGC

18. Feb. 2026, 21:56 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Avita Therapeutics Inc Prognose

Kursziel

By TipRanks

8.17% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD 8.17%

Hoch 5.5 USD

Tief 3.5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Avita Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Avita Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

8.83 / 9.77Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.